Aged (at least 18 years old)
Showing 26 - 50 of >10,000
Irritable Bowel Syndrome, Diarrhea- Irritable Bowel Syndrome, Constipation-predominant Irritable Bowel Syndrome Trial (Short
Not yet recruiting
- Irritable Bowel Syndrome
- +2 more
- Short Chain Fructooligosaccharides
- Corn Starch
- (no location specified)
Jul 3, 2023
Renal Allograft Recipients Trial in Worldwide (Belatacept, Tacrolimus, Cyclosporine A)
Recruiting
- Renal Allograft Recipients
- Belatacept
- +5 more
-
Birmingham, Alabama
- +14 more
Oct 24, 2022
Effectiveness of the COVID-19 Inactivated Vaccine
Active, not recruiting
- COVID-19
- SARS-CoV-2 vaccine (Vero cell) inactivated
-
Bandung, Indonesia
- +3 more
Sep 4, 2022
Respiratory Syncytial Virus Infection Prevention Trial in Worldwide (Ad26.RSV.preF-based Vaccine, Placebo)
Completed
- Respiratory Syncytial Virus Infection Prevention
- Ad26.RSV.preF-based Vaccine
- Placebo
-
Coral Gables, Florida
- +22 more
Sep 27, 2022
Covid19 Trial in United States (sotrovimab)
Recruiting
- Covid19
- sotrovimab
-
Riverside, California
- +9 more
Nov 2, 2022
Long-lasting Adaptation to Endurance and Speed-power Training on
Active, not recruiting
- Healthy Athletes Aged 18-35 Years
- Sprint training
- +2 more
-
Poznań, Wielkoolska, PolandPoznan University of Physical Education
Jan 5, 2023
Herpes Zoster Trial in Tomball (HZ/su, Flu D-QIV, mRNA-1273)
Active, not recruiting
- Herpes Zoster
- HZ/su
- +2 more
-
Tomball, TexasGSK Investigational Site
Apr 8, 2022
HPV Infection Trial in Mianyang (Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris))
Active, not recruiting
- HPV Infection
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
-
Mianyang, Sichuan, ChinaMianyang Center for Disease Control and Prevention
Jul 7, 2021
Influenza Trial in Ghent (OVX836-003, Saline solution)
Recruiting
- Influenza
- OVX836-003
- Saline solution
-
Ghent, BelgiumCentre for Vaccinology (CEVAC)
Apr 27, 2022
SARS-CoV2 COVID-19 Trial in Randwick, Adelaide, Perth (COVIGEN C19 0.8 mg ID or Placebo ID, COVIGEN C19 2.0 mg IM or Placebo IM,
Active, not recruiting
- SARS-CoV2 COVID-19
- COVIGEN C19 0.8 mg ID or Placebo ID
- +3 more
-
Randwick, New South Wales, Australia
- +2 more
Nov 17, 2022
Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections Trial in Shangqiu (Protein based pneumococcal vaccine(Low
Completed
- Pneumonia
- +2 more
- Protein based pneumococcal vaccine(Low dose)
- +5 more
-
Shangqiu, Henan, ChinaSuixian Center for Disease Control and Prevention
Nov 3, 2022
SARS-CoV2, Covid19 Trial in Herston (MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg, MF59 adjuvanted SARS-CoV-2 Sclamp vaccine
Active, not recruiting
- SARS-CoV2
- Covid19
- MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
- +3 more
-
Herston, Queensland, AustraliaNucleus Network Brisbane (Q-Pharm Pty Ltd)
Aug 23, 2021
COVID-19 Trial in Nanjing (Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14,
Recruiting
- COVID-19
- Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14
- +7 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Diseases Control and Prevention
Mar 28, 2022
Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma Trial in Lyon (PASCA intervention)
Recruiting
- Late Effects
- +8 more
- PASCA intervention
-
Lyon, FranceCentre Leon Berard
Mar 15, 2022
Prevention of COVID19 Trial (mRNA-1273)
Not yet recruiting
- Prevention of COVID19
- mRNA-1273
- (no location specified)
Feb 6, 2021
Healthy Volunteers Trial (Purified Inactivated Zika Virus Vaccine (PIZV), Placebo)
Not yet recruiting
- Healthy Volunteers
- Purified Inactivated Zika Virus Vaccine (PIZV)
- Placebo
- (no location specified)
Jul 25, 2022
Covid19 Trial in Caba, Capital Federal (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV))
Recruiting
- Covid19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
-
Caba, Buenos Aires, Argentina
- +3 more
Sep 14, 2021
COVID-19 Trial in Wuhan (Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector))
Completed
- COVID-19
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
-
Wuhan, Hubei, ChinaHubei Provincial Center for Disease Control and Prevention
Aug 2, 2021
COVID-19 Trial in Nanjing (Recombinant COVID-19 vaccine (Sf9 cells), Placebo)
Withdrawn
- COVID-19
- Recombinant COVID-19 vaccine (Sf9 cells)
- Placebo
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Diseases Control and Prevention
May 21, 2021
Upadacitinib of Enthesitis Evaluated by Ultrasound in Psoriatic
Not yet recruiting
- Psoriatic Arthritis
-
Madrid, SpainInstituto de Investigación Sanitaria Fundación Jiménez Díaz
Nov 25, 2023
Influenza Trial (Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator)
Withdrawn
- Influenza
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2)
- Comparator
- (no location specified)
Mar 19, 2021
COVID-19 Trial in Xuzhou (Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two
Completed
- COVID-19
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
- +11 more
-
Xuzhou, Jiangsu, ChinaSuining County Center for Disease Control and Prevention
Feb 22, 2022
Withdrawal or Reduction TKIs in CML-CP
Recruiting
- MMR on 12 Month
- withdrawal TKIs or halve TKIs
-
Guangzhou, Guangdong, ChinaNanfangH
Sep 2, 2021